ARQT Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 27.14%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 1.49%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 35.51%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.

Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 23.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 12.52x versus 10.12x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ANI Pharmaceuticals, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 10.59%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.

Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 1.49%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.88 which suggests that it could grow by 32.8%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.

Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 50.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 12.52x versus 2.02x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Editas Medicine, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of -332.98%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat Editas Medicine, Inc.'s return on equity of -246.73%.

Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 1.49%. On the other hand Editas Medicine, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 110.91%. Given that Editas Medicine, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Editas Medicine, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison Editas Medicine, Inc. has a beta of 2.441, suggesting its more volatile than the S&P 500 by 144.07%.

Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. Editas Medicine, Inc. pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are larger than Editas Medicine, Inc. quarterly revenues of $7.5M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is higher than Editas Medicine, Inc.'s net income of -$25.1M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Editas Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 12.52x versus 4.46x for Editas Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Syndax Pharmaceuticals, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of -132.36%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat Syndax Pharmaceuticals, Inc.'s return on equity of -136.36%.

Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 1.49%. On the other hand Syndax Pharmaceuticals, Inc. has an analysts' consensus of $39.31 which suggests that it could grow by 99.13%. Given that Syndax Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Syndax Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison Syndax Pharmaceuticals, Inc. has a beta of 0.476, suggesting its less volatile than the S&P 500 by 52.361%.

Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. Syndax Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are larger than Syndax Pharmaceuticals, Inc. quarterly revenues of $45.9M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is higher than Syndax Pharmaceuticals, Inc.'s net income of -$60.7M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Syndax Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 12.52x versus 15.26x for Syndax Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.